EA200300464A1 - ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ - Google Patents

ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ

Info

Publication number
EA200300464A1
EA200300464A1 EA200300464A EA200300464A EA200300464A1 EA 200300464 A1 EA200300464 A1 EA 200300464A1 EA 200300464 A EA200300464 A EA 200300464A EA 200300464 A EA200300464 A EA 200300464A EA 200300464 A1 EA200300464 A1 EA 200300464A1
Authority
EA
Eurasian Patent Office
Prior art keywords
human life
published
methods
relates
antibodies against
Prior art date
Application number
EA200300464A
Other languages
English (en)
Other versions
EA006945B1 (ru
Inventor
Эллен Гарбер
Пол Лайн
Хосе У. Сальдана
Original Assignee
Байоджен, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен, Инк. filed Critical Байоджен, Инк.
Publication of EA200300464A1 publication Critical patent/EA200300464A1/ru
Publication of EA006945B1 publication Critical patent/EA006945B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Изобретение относится к гуманизированным антителам против LT-β-R и способам их применения.Отчет о международном поиске был опубликован 2003.03.13.
EA200300464A 2000-10-13 2001-10-12 ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ (ВАРИАНТЫ) EA006945B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24028500P 2000-10-13 2000-10-13
US27528901P 2001-03-13 2001-03-13
US29998701P 2001-06-21 2001-06-21
PCT/US2001/032140 WO2002030986A2 (en) 2000-10-13 2001-10-12 HUMANIZED ANTI-LT-β-R ANTIBODIES

Publications (2)

Publication Number Publication Date
EA200300464A1 true EA200300464A1 (ru) 2003-10-30
EA006945B1 EA006945B1 (ru) 2006-06-30

Family

ID=27399340

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300464A EA006945B1 (ru) 2000-10-13 2001-10-12 ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ (ВАРИАНТЫ)

Country Status (25)

Country Link
US (2) US7429644B2 (ru)
EP (1) EP1326897A2 (ru)
JP (1) JP2004532608A (ru)
KR (1) KR20030041164A (ru)
CN (1) CN1547590A (ru)
AR (1) AR035352A1 (ru)
AU (2) AU1174702A (ru)
BG (1) BG107802A (ru)
BR (1) BR0114646A (ru)
CA (1) CA2425809A1 (ru)
CZ (1) CZ20031307A3 (ru)
EA (1) EA006945B1 (ru)
EE (1) EE200300179A (ru)
GE (1) GEP20063752B (ru)
HU (1) HUP0302573A2 (ru)
IL (1) IL155340A0 (ru)
IS (1) IS6779A (ru)
MX (1) MXPA03003144A (ru)
NO (1) NO20031642L (ru)
NZ (1) NZ525793A (ru)
PL (1) PL366307A1 (ru)
SK (1) SK5672003A3 (ru)
TR (2) TR200300478T2 (ru)
WO (1) WO2002030986A2 (ru)
YU (1) YU28503A (ru)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
AR040367A1 (es) * 2002-07-01 2005-03-30 Biogen Inc Anticuerpos humanizados contra el receptor de linfotoxina beta
CA2509495A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
WO2004058191A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
JP5091476B2 (ja) 2003-06-27 2012-12-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
CN1980957A (zh) * 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 受体偶联剂及其治疗用途
US8153123B2 (en) * 2004-12-09 2012-04-10 La Jolla Institute For Allergy And Immunology Method for restoring dendritic cell populations
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
BRPI0619657A2 (pt) 2005-11-04 2011-11-08 Genentech Inc métodos de prevenção ou melhoria de doença ocular, uso de um inibidor de complemento, uso de um sirna especìfico para uma proteìna do sistema complemento e uso de um ácido nucleico que codifica um inibidor do sistema complemento
JP2007295524A (ja) * 2006-03-28 2007-11-08 Denso Corp 情報通信システム、施設側装置、ユーザ側装置、管理装置、車両側装置、施設側プログラム、ユーザ側プログラム、管理プログラム及び車両側プログラム
AR061115A1 (es) * 2006-05-25 2008-08-06 Glaxo Group Ltd Anticuerpos anti- interleuquina 18 (il-18)
EP2067041A2 (en) 2006-10-03 2009-06-10 Biogen Idec MA, Inc. Biomarkers and assays for the treatment of cancer
RU2486201C2 (ru) * 2006-10-12 2013-06-27 Дженентек, Инк. Антитела к лимфотоксину-альфа
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
NZ576424A (en) * 2006-10-20 2012-09-28 Biogen Idec Inc Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
KR20190003860A (ko) 2006-11-02 2019-01-09 제넨테크, 인크. 인간화 항-ｄ 인자 항체
US8003761B2 (en) * 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
SI2158315T1 (sl) 2007-06-25 2016-05-31 Esbatech, An Alcon Biomedical Research Unit Llc Postopki za spreminjanje protiteles in spremenjena protitelesa z izboljšanimi funkcionalnimi lastnostmi
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
US8846042B2 (en) 2011-05-16 2014-09-30 Fabion Pharmaceuticals, Inc. Multi-specific FAB fusion proteins and methods of use
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
SG11201601044XA (en) 2013-08-12 2016-03-30 Genentech Inc Compositions and method for treating complement-associated conditions
JP2017515811A (ja) 2014-05-01 2017-06-15 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体及びその使用法
EP3611188B1 (en) 2014-11-06 2022-05-04 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn-binding and methods of use
CN108135969B (zh) 2015-07-14 2022-03-04 里姆蒙埃克斯特股份有限公司 具有改善的结合、功能和安全性特征的抗cd154抗体及其在人免疫治疗中的用途
JP2018536650A (ja) 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体コンジュゲート及びその使用
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
EP3430058A4 (en) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
CN115087670A (zh) 2019-12-11 2022-09-20 西拉格国际有限责任公司 包含ltbr和edb结合结构域的多特异性结合分子及其用途
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
CR20240246A (es) 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023218320A1 (en) * 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
WO2024211478A1 (en) 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a lymphotoxin beta receptor agonist

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JPH06501456A (ja) 1990-06-27 1994-02-17 バイオジェン，インコーポレイテッド 表面複合リンホトキシン
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0672143B1 (en) 1992-12-04 2008-06-04 Biogen Idec MA Inc. Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preparations and therapeutic uses thereof
NZ303405A (en) * 1995-01-26 2000-02-28 Biogen Inc lymphotoxin-alpha and lymphotoxin-beta heteromeric complexes to treat neoplasia
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
EP1051187B9 (en) 1998-01-30 2004-08-11 Biogen, Inc. Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
AR040367A1 (es) * 2002-07-01 2005-03-30 Biogen Inc Anticuerpos humanizados contra el receptor de linfotoxina beta
WO2004058191A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
CA2509495A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Lymphotoxin beta receptor agents in combination with chemotherapeutic agents

Also Published As

Publication number Publication date
PL366307A1 (en) 2005-01-24
IS6779A (is) 2003-04-11
NO20031642L (no) 2003-06-13
CZ20031307A3 (cs) 2003-10-15
BG107802A (bg) 2004-01-30
BR0114646A (pt) 2006-02-21
EP1326897A2 (en) 2003-07-16
EE200300179A (et) 2003-08-15
MXPA03003144A (es) 2004-12-06
CN1547590A (zh) 2004-11-17
IL155340A0 (en) 2003-11-23
NO20031642D0 (no) 2003-04-10
WO2002030986A3 (en) 2003-03-13
AU1174702A (en) 2002-04-22
YU28503A (sh) 2006-05-25
US7429644B2 (en) 2008-09-30
HUP0302573A2 (hu) 2003-10-28
US20090092601A1 (en) 2009-04-09
WO2002030986A2 (en) 2002-04-18
SK5672003A3 (en) 2003-10-07
TR200300478T2 (tr) 2004-10-21
JP2004532608A (ja) 2004-10-28
KR20030041164A (ko) 2003-05-23
AR035352A1 (es) 2004-05-12
US20040058394A1 (en) 2004-03-25
AU2002211747B2 (en) 2007-11-29
CA2425809A1 (en) 2002-04-18
NZ525793A (en) 2008-04-30
EA006945B1 (ru) 2006-06-30
GEP20063752B (en) 2006-02-27
TR200602095T2 (tr) 2007-02-21

Similar Documents

Publication Publication Date Title
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
EA200100773A1 (ru) Замещенные 1-гетероциклические диариламины
EA200201214A1 (ru) Замещенные тиоацетамиды
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
NO20041917D0 (no) Spesifikke midler som binder humant angiopoietin-2
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
EA200400241A1 (ru) Направленные к мишени мультимерные контрастные вещества, основанные на пептидах
EA200500520A1 (ru) Пуриновые соединения и их применение в качестве лигандов каннабиноидных рецепторов
EA200300566A1 (ru) Применение cci-779 в качестве противоопухолевого средства
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
EA200400510A1 (ru) Агенты, специфически связывающие ангиопоэтин-2
CY1105836T1 (el) 12, 13-τροποποιημενα παραγωγα εποθιλονης
IL195338A0 (en) Optimized fc variants and methods for their generation
EA200301215A1 (ru) Лиганды рецепторов 5-ht и их применение
EA200401341A1 (ru) Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
DK1083903T3 (da) Brobundne indenopyrrolocarbazoler
IL166021A0 (en) Trabsolant acceptance inducing cells of monocytic origin and their preparation and use
EA200201138A1 (ru) Пептид, модулирующий рецептор тромбопоэтина
DE50111331D1 (de) Neue verwendung von proteinhydrolysaten
EA200200974A1 (ru) Моноклональные антитела к рецептору лпнп человека, их получение и применение
BR0015872A (pt) Agentes antitrombóticos
EA200100854A1 (ru) Кальций-литические соединения
EA199800753A1 (ru) Бензотиофены, составы их содержащие и способы с их использованием
EA200200798A1 (ru) Кальцилитические соединения
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение

Legal Events

Date Code Title Description
HC1A Change in name of an applicant in a eurasian application
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU